AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

100 people who followed a low-carb keto diet were analyzed and high cholesterol was found to not be a marker for increased ...

(AP Photo/Alastair Grant, File) (NewsNation) — AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment ...

The global organ on a chip market was valued at US$ 157.06 million in 2024 and is expected to reach US$ 2,238.28 million by ...

The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is ...